Emmanuel L. Gautier 1 , Marit Westerterp 2 , 3 , Neha Bhagwat 4 , 5 , Serge Cremers 2 , Alan Shih 4 , 5 , Omar Abdel-Wahab 4 , 5 , Dieter Lütjohann 6 , Gwendalyn J. Randolph 1 , Ross L. Levine 4 , 5 , Alan R. Tall 2 , Laurent Yvan-Charvet , 2 , 7
11 February 2013
Elevating HDL levels reduces Glut1 expression, dampens myeloproliferation, and prevents fat loss in multiple mouse models.
A high metabolic rate in myeloproliferative disorders is a common complication of neoplasms, but the underlying mechanisms are incompletely understood. Using three different mouse models of myeloproliferative disorders, including mice with defective cholesterol efflux pathways and two models based on expression of human leukemia disease alleles, we uncovered a mechanism by which proliferating and inflammatory myeloid cells take up and oxidize glucose during the feeding period, contributing to energy dissipation and subsequent loss of adipose mass. In vivo, lentiviral inhibition of Glut1 by shRNA prevented myeloproliferation and adipose tissue loss in mice with defective cholesterol efflux pathway in leukocytes. Thus, Glut1 was necessary to sustain proliferation and potentially divert glucose from fat storage. We also showed that overexpression of the human ApoA-I transgene to raise high-density lipoprotein (HDL) levels decreased Glut1 expression, dampened myeloproliferation, and prevented fat loss. These experiments suggest that inhibition of Glut-1 and HDL cholesterol–raising therapies could provide novel therapeutic approaches to treat the energy imbalance observed in myeloproliferative disorders.